H2O America Q3 2026 slides: Texas bet drives growth amid dilution

H2O America reported Q3 adjusted diluted EPS of $1.04, down 18% year over year and below Wall Street estimates, as share dilution reduced EPS by $0.22. It completed the $540 million Quadvest acquisition on October 1 and introduced 2026 adjusted EPS guidance of $2.91–$2.97 including the deal; management expects 2027 dilution of 10–20% and Quadvest accretion beginning in 2028. The company maintained its $2.7 billion 2026–2030 capital plan and 6–8% long-term EPS CAGR target, while shares rose 3.8% to $60.71.

Analysis

The key issue is the gap between rate-base growth and shareholder earnings: acquisition-related share dilution, added depreciation and financing costs delay EPS benefits even if customer and infrastructure growth deliver. That makes the 2028 accretion promise—not the 13% rate-base CAGR—the central underwriting variable. The market’s positive reaction may reflect a willingness to look through near-term dilution, but the 2027 EPS drag leaves limited room for execution or regulatory slippage.

Texas is the clearest challenge to the recovery thesis. The system-improvement decision turned a requested increase into a small decrease, a warning that planned capital spending does not automatically convert into timely earnings. The planned Texas rate case is therefore a material catalyst, not routine process. Connecticut’s proposed decision in December is the nearer test of whether infrastructure investment can earn the requested returns; Maine’s expected 2027 rates and California’s PFAS recovery decision extend the catalyst path.

Over 6–18 months, watch whether debt funding and the remaining forward shares keep FFO/debt comfortably above the stated 11% downgrade threshold, and whether management preserves its no-new-equity commitment through 2027. The thesis weakens if regulatory recovery disappoints or dilution/depreciation push EPS below guidance; it strengthens if rate decisions support recovery and 2027 earnings track toward the promised 2028 accretion. The Texas outcome cautions against treating the 80% timely-recovery estimate as uniform across jurisdictions.

Key Decisions for Investors

• Do not chase the post-results rally. Treat HTO as a catalyst-driven hold/watch rather than a clean growth purchase until the Texas GRC filing and Connecticut proposed decision clarify realized recovery.
• For existing HTO exposure, size against the 2027 dilution window; reassess if guidance is cut, the no-additional-equity commitment changes, or FFO/debt approaches the 11% downgrade threshold.
• A constructive add signal would be regulatory decisions that recover invested capital on schedule while management maintains EPS guidance and its 2028 accretion trajectory. Failure of either would challenge the rate-base-growth thesis.
• No options trade is warranted from the available information: option pricing, valuation context and the market’s expectations for the pending rate cases are missing. Monitor those inputs rather than pay for an unquantified catalyst.